Review Article
Cardiovascular Risk in Patients with Psoriatic Arthritis
Table 1
Mortality studies in psoriatic arthritis.
| Study | Year | Country | no. of patients | Male, no. [%] | Follow-up period | SMR (95% CI) | Remarks | Major causes of death |
| Roberts et al. [11] | 1976 | UK | 168 | — | — | — | 18 deaths occurred | 9 deaths due to CVD | Coulton et al. [13] | 1989 | UK | 40 | 16 (40) | 8 years | — | No deaths occurred | — | Wong et al. [8] | 1997 | Canada | 428 | 234 (54.7) | 1978 –1993 | Overall: 1.62 (1.21–2.12) Male: 1.65 (1.09, 2.04) Female: 1.59 (1.04, 2.33) | — | CVD (36.2%), respiratory disease (21.3%) | Shbeeb et al. [10] | 2000 | US | 66 | 32 (48.5) | 1982–1991 | — | Similar survival to the general population | — | McHugh et al. [3] | 2003 | UK | 87 | 38 (57.6) | Median: 65 months | — | 9 deaths occurred | 5 deaths due to CVD | Alamanos et al. [16] | 2003 | North-west Greece | 221 | 108 (48.9) | 1982–2001 | — | 4 deaths occurred | 2 deaths due to CVD | Ali et al. [15] | 2007 | Canada | 680 | 385 (56.6) | 1978–2004 | Overall: 1.36 (1.12–1.64) Male: 1.25 (0.95, 1.65) Female: 1.47 (1.13, 1.91) | — | Malignancy (23.6%), CVD (24.5%), respiratory diseases (10.4%) | Wilson et al. [9] | 2009 | US | 147 | 90 (61) | 1970–1999 | 0.91 (0.58, 1.37) | — | — | Buckley et al. [14] | 2010 | UK | 453 | 232 (51.2) | 1985–2007 | Overall: 0.82 (0.58–1.13) Male: 0.68 (0.39, 1.10) Female: 0.97 (0.60, 1.48) | — | CVD (38%), respiratory disease (27%), malignancy (14%) | Ahlehoff et al. [17] | 2010 | Denmark | 607 | — | 1997–2006 | — | RR for all-cause mortality*: 1.74 (1.32–2.30); RR for cardiovascular death: 1.84 (1.11–3.06) | — | Mok et al. [12] | 2011 | Hong Kong | 778 | 424 (54) | 1999–2008 | Overall: 2.50 (1.81–3.19) Male: 2.27 (1.44, 3.10) Female: 2.76 (1.61, 3.91) | — | Infection (33%), malignancy (20%), CVD (20%) |
|
|
SMR: standardized mortality ratio; CI: confidence interval; UK: United Kingdom; CVD: cardiovascular disease; US: United States; RR: relative risk.
*Rate ratio (95% confidence interval) compared with 4,003,265 controls, adjusted for age, calendar year, concomitant medication, comorbidity, socio-economic data and gender.
|